The Efficacy and Safety of Transdermal Scopolamine for the Prevention of Postoperative Nausea and Vomiting: A Quantitative Systematic Review
Authors:
- Peter KrankePKPeter Kranke
- Astrid M. MorinAMAstrid M. Morin
- Norbert RoewerNRNorbert Roewer
- Hinnerk WulfHWHinnerk Wulf
- Leopold H. EberhartLELeopold H. Eberhart
- 1 July 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 95 (1) , 133-143
Abstract
The role of scopolamine administered via transdermal therapeutic systems in the prevention of postoperative vomiting, nausea, and nausea and vomiting is unclear. We performed a systematic search for full reports of randomized comparisons of transdermal scopolamine with inactive control. Dichotomous data were extracted. In the meta-analysis, relative risks and numbers-needed-to-treat/harm were calculated with 95% confidence intervals (CI). In 23 trials, 979 patients received transdermal scopolamine, and 984 patients received placebo. Sensitivity analyses were performed using restricted data for truncated control event rates (40%–80%) and for large trials. With these data, the relative risks for postoperative vomiting (five reports), nausea (five reports), nausea and vomiting (eight reports), and rescue treatment (three reports) were 0.69 (95% CI, 0.58–0.82), 0.69 (95% CI, 0.54–0.87), 0.76 (95% CI, 0.66–0.88), and 0.68 (95% CI, 0.54–0.85), respectively. This means that of 100 patients who receive transdermal scopolamine, approximately 17 will not experience postoperative vomiting who would have done so had they all received a placebo. However, 18 of 100 patients will have visual disturbances, eight will report dry mouth, two will report dizziness, one will be classified as being agitated, and 1–13 patients who are prescribed transdermal scopolamine will not use it correctly. The timing of application does not alter efficacy.Keywords
This publication has 44 references indexed in Scilit:
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- Efficacy, Dose-Response, and Safety of Ondansetron in Prevention of Postoperative Nausea and VomitingAnesthesiology, 1997
- Epidural scopolamine administration in preventing nausea after epidural morphineJournal of Clinical Anesthesia, 1995
- Rectal versus intramuscular morphine‐scopolamine as premedication in childrenActa Anaesthesiologica Scandinavica, 1995
- ANAESTHESIA, MOVEMENT AND EMESISBritish Journal of Anaesthesia, 1990
- Premedication with intramuscular dixyrazine: (Esucos®)Acta Anaesthesiologica Scandinavica, 1988
- Premedication with midazolam in out‐patient general anaesthesia. A comparison with morphine‐scopolamine and placeboActa Anaesthesiologica Scandinavica, 1987
- Premedication for day‐case surgery: double‐blind comparison of ketobemidone + dimethylaminodiphenylbuten (A‐29) and morphine + scopolamineActa Anaesthesiologica Scandinavica, 1986
- Comparison of Rectal Diazepam and Subcutaneous Morphine-Scopolamine Administration for Outpatient Sedation in Minor Oral SurgeryActa Anaesthesiologica Scandinavica, 1985
- Transdermal Hyoscine (Scopolamine) A Preliminary Review of its Pharmacodynamic Properties and Therapeutic EfficacyDrugs, 1985